Vladimír Bzdúch, Katarína Jariabková, Radka Včasná, Katarína Fabriciová, Darina Behúlová
Mucopolysaccharidosis type II (Hunter syndrome) is a rare X-linked lysosomal storage disorder, caused by iduronate-2-sulfatase deficiency, an enzyme needed to break down specific glycosaminoglycans. Assesment of increased urinary glycosaminoglycans (heparan and dermatan sulphate) is the basic screening test, but for definite diagnosis additional tests must be performed. Clinical manifestations of the disease are multisystemic involving abnormal facial features, organomegaly, skeletal dysplasia and limited mobility. Patients with a severe phenotype have profound neurological disturbances. Characteristic are delayed psychomotor development and behaviour disturbances. Enzyme replacement therapy, which is available from 2008, has beneficial effects on certain somatic signs and symptoms.